Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2010 063 083.8 |
96 | EP file number | EAKZ | 10 82 5726.2 |
86 | WO file number | WAKZ | PCT/US2010/053686 |
97 | EP publication number | EPN | 2490720 |
87 | WO publication number | WPN | 2011050242 |
54 | Designation/title | TI | ANTI-GCC-ANTIKÖRPERMOLEKÜLE SOWIE ENTSPRECHENDE ZUSAMMENSETZUNGEN UND VERFAHREN |
51 | IPC main class | ICM (ICMV) | C07K 16/30 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 39/395 (2006.01) |
22 | DE application date | DAT | Oct 22, 2010 |
96 | EP application date | EAT | Oct 22, 2010 |
86 | WO application date | WAT | Oct 22, 2010 |
43 | Date of first publication | OT | Apr 28, 2011 |
| Date of publication of grant | PET | Feb 12, 2020 |
71/73 | Applicant/owner | INH | Amgen British Columbia, Burnaby, BC, CA; Takeda Pharmaceutical Company Limited, Osaka-shi, JP |
72 | Inventor | IN | NAM, Samuel, S., Haverhill, MA 01832, US; GREENFIELD, Edward, A., Stoughton, MA 02072, US; BABCOOK, John, Vancouver, BC V6R 2R2, CA; O'KEEFE, Theresa, Waltham, MA 02453, US; QIN, Shixin, Lexington, MA 02421, US |
| Address for service | | Kilburn & Strode LLP, London WC1X 8NL, GB |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 254474 P Oct 23, 2009
|
| Due date | FT FG | Oct 31, 2025 Annual fee for the 16th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000002490720 Searchable text:
EP000002490720 Original document:
EP000002490720B1 Searchable text:
EP000002490720B1 Original document:
WO002011050242 Searchable text:
WO002011050242 |
43 | Date of first publication | EVT | Apr 28, 2011 |
| Date of the first transfer into DPMAregister | EREGT | Oct 12, 2012 |
| Date of the (most recent) update in DPMAregister | REGT | Jan 11, 2025 (Show all update days)(Hide all update days)- Jan 11, 2025
- Nov 13, 2024
- Procedures: Procedure relating to PCT application, Publication of PCT application, 28.04.2011: deleted
- Sep 29, 2023; Sep 30, 2022; Jan 5, 2022; Nov 30, 2021; Oct 30, 2021; Feb 5, 2021; Dec 31, 2020; Nov 4, 2020; May 12, 2020; Mar 5, 2020; Jan 24, 2020; Jan 23, 2020; Aug 13, 2019; Feb 28, 2019; Sep 27, 2018; Jul 28, 2016; Feb 16, 2013
- Historical data not available for this/these date(s)
- Oct 12, 2012
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 8)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Nov 29, 2021 |
| Issue number | HN | 1 |
| Year | PJ | 2022 |
| Publication date | VT | Jan 5, 2022 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Amgen British Columbia, Burnaby, BC, CA; Takeda Pharmaceutical Company Limited, Osaka-shi, JP |
71/73 | Previous applicant/owner | INHF | Amgen British Columbia, Burnaby, BC, CA, Millennium Pharmaceuticals, Inc., Cambridge, Mass., US |
| Date of update of the procedure | REGT | Jan 5, 2022 |